Cancerous disease modifying antibodies
AssigneeArius Research, Inc.
InventorsDavid S. F. Young, Susan E. Hahn, Helen P. Findlay
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
Claims16
An isolated monoclonal antibody encoded by the clone deposited with the ATCC as Accession Number PTA-4890.
The isolated clone deposited with the ATCC as Accession Number PTA-4890.
A method for initiating antibody induced cellular cytotoxicity of cancerous cells in a tissue sample selected from a human breast or prostrate tumor comprising:
- providing a tissue sample from said human breast or prostate tumor;
- providing the monoclonal antibody encoded by the clone deposited with the ATCC as Accession Number PTA-4890 or a cellular cytotoxicity inducing antigen binding fragment thereof;
- and
- contacting said isolated monoclonal antibody or cellular cytotoxicity inducing antigen binding fragment thereof with said tissue sample.
A method of treating human breast and prostate tumors susceptible to antibody induced cellular cytotoxicity in a mammal, wherein said human breast and prostrate tumors express an antigen which specifically binds to the monoclonal antibody encoded by a clone deposited with the ATCC as accession number PTA-4890 or a cellular cytotoxicity inducing antigen binding fragment thereof, comprising administering to said mammal said monoclonal antibody or said antigen binding fragment thereof in an amount effective to induce cellular cytotoxicity and thereby reduce said mammal's tumor burden.
Dependencies are inferred from the claim text.